Federal judges in Texas and Connecticut on Thursday ruled against arguments challenging the constitutionality of the Medicare ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Pharma industry loses on Medicare price ...

Drug companies have formed a new group to present lawmakers with research on what the industry sees as the negative impacts ...

Three federal courts reject legal challenges to Medicare drug price negotiation Judges side with government in cases filed by ...

The drug industry’s top lobbying group is appealing its latest loss in its challenge to Medicare’s Drug Price Negotiation Program to the Fifth Circuit, returning the case to an appeals court that has ...

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

The Inflation Reduction Act (IRA) authorized the federal government to force prescription drug manufacturers to "negotiate" drug prices for ...

The Health Resources and Services Administration (HRSA) issued a notice announcing the application process for the 340B rebate model pilot program ...

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, ...

A voluntary rebate pilot for the 340B drug discount program is drawing attention as a potential way to address concerns over ...

Drug companies and organizations challenging the Medicare drug negotiations have yet to convince a U.S. court that the process, mandated by the 2022 Inflation Reduction Act, violates the Constitution.

A normally hard-headed bench just endorsed President Biden’s scheme to dictate how much drugmakers can charge under Medicare.